a Department of Pediatrics, Desio Hospital , ASST Monza , Desio (MB) , Italy.
b PhD student in Biomedical Sciences , University of Florence , Florence , Italy.
Expert Rev Clin Immunol. 2019 Feb;15(2):189-198. doi: 10.1080/1744666X.2019.1550359. Epub 2018 Nov 30.
: Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine involved in the pathogenesis of many inflammatory diseases. Several drugs blocking TNF-α are employed in clinical practice in pediatrics. Given their action on the immune system, TNF-α inhibitors have raised concerns on their safety profile since their introduction. A broad spectrum of side effects related to TNF inhibition has been reported: immunogenicity, infectious diseases, malignancies, and others. : In order to assess the risk related to the use of anti-TNF-α agents in children with rheumatic diseases we analyzed data obtained from retrospective and prospective safety studies, case reports and case series, and controlled trials. : Anti-TNF-α agents have shown a remarkably good safety profile in the pediatric population so far. However, there are lots of questions to be answered and maintaining active surveillance on these drugs is necessary in order to not overlook any possible unexpected adverse effects.
肿瘤坏死因子-α（TNF-α）是一种参与许多炎症性疾病发病机制的促炎细胞因子。在儿科临床实践中，有几种阻断 TNF-α 的药物。鉴于它们对免疫系统的作用，TNF-α抑制剂自问世以来，其安全性一直备受关注。已报道了与 TNF 抑制相关的广泛的副作用：免疫原性、传染病、恶性肿瘤等。为了评估抗 TNF-α 药物在风湿性疾病儿童中的使用风险，我们分析了来自回顾性和前瞻性安全性研究、病例报告和病例系列以及对照试验的数据。迄今为止，抗 TNF-α 药物在儿科人群中的安全性良好。然而，仍有许多问题需要解答，有必要对这些药物进行主动监测，以免忽视任何可能的意外不良反应。
